
An exceptionally pricey gene therapy cure for sickle cell disease could soon be available, but it’s not clear whether insurance companies will balk at the cost and deny coverage. On the surface, the gene therapy does not appear as cost-effective as the grinding medical care that sickle cell patients now receive, according to a new… read on > read on >